Abstract library

33 results for "Lopez".
#828 Challenging in Predicting Response in Treatment of Neuroendocrine Pancreatic Tumors: Nutritional Factors
Introduction: Neuroendocrine pancreatic tumors (NEPT) include a heterogeneous neoplasms group in pathophysiology, clinical manifestations, treatment and prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Cristina Tejera
#991 Primary Neuroendocrine Tumor of Extrahepatic Bile Duct
Introduction: Biliary tract primary malignant tumors are rare neoplasms. Eighty-five per cent are cholangiocarcinomas, being in exceptional cases a neuroendocrine tumor. The absence of clinical suspiction involves a difficult preoperative diagnosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Jose Angel Flores Garcia
#1004 Prognostic Value of Histophathological Features of Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (NETs) are rare neoplasms. NETs are clinically diverse and can be divided into functioning and non-functioning tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD Ernesto Jesus Barzola Navarro
#1488 Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs)
Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Caroline Lopez
#746 Aspirin Delays the Development/Progression of Neuroendocrine Pancreatic Neoplasms and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors
Introduction: So far, there are no chemopreventive strategies for neuroendocrine pancreatic neoplasms.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Prof.Dr. Volker Fendrich
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#950 Outcome of Malignant Insulinomas (MI) in the Community Setting
Introduction: MI is a rare and difficult to handle functional pancreatic neuroendocrine tumor with a variety of therapeutic alternatives.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: MD Carlos Lopez Lopez
#1052 Appendiceal Goblet Cell Carcinoids: Prognostic Factors and Selection of the Most Appropriate Adjuvant Management in a Retrospective Series.
Introduction: Appendiceal goblet cell carcinoids (GCC) are rare tumours with low-quality data regarding its management
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Angela Lamarca
Keywords: Goblet cell, appendix
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1213 Everolimus (EVE)-Induced Hyperglycemia (HG) in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs): Clinical Relevance and Predictive Value
Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.